You are here

ACS Med Chem Lett DOI:10.1021/acsmedchemlett.6b00264

Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1.

Publication TypeJournal Article
Year of Publication2016
AuthorsLaw, JM, Stark, SC, Liu, K, Liang, NE, Hussain, MM, Leiendecker, M, Ito, D, Verho, O, Stern, AM, Johnston, SE, Zhang, Y-L, Dunn, GP, Shamji, AF, Schreiber, SL
JournalACS Med Chem Lett
Volume7
Issue10
Pages944-949
Date Published2016 Oct 13
ISSN1948-5875
Abstract

Evidence suggests that specific mutations of isocitrate dehydrogenases 1 and 2 (IDH1/2) are critical for the initiation and maintenance of certain tumor types and that inhibiting these mutant enzymes with small molecules may be therapeutically beneficial. In order to discover mutant allele-selective IDH1 inhibitors with chemical features distinct from existing probes, we screened a collection of small molecules derived from diversity-oriented synthesis. The assay identified compounds that inhibit the IDH1-R132H mutant allele commonly found in glioma. Here, we report the discovery of a potent (IC50 = 50 nM) series of IDH1-R132H inhibitors having 8-membered ring sulfonamides as exemplified by the compound BRD2879. The inhibitors suppress (R)-2-hydroxyglutarate production in cells without apparent toxicity. Although the solubility and pharmacokinetic properties of the specific inhibitor BRD2879 prevent its use in vivo, the scaffold presents a validated starting point for the synthesis of future IDH1-R132H inhibitors having improved pharmacological properties.

DOI10.1021/acsmedchemlett.6b00264
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/27774134?dopt=Abstract

Alternate JournalACS Med Chem Lett
PubMed ID27774134
PubMed Central IDPMC5066158